Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8087823 | 0.79 | HRH3 (0.50) | ALDH1A1KDM4EAOC3HRH3HRH4 | |
| SCHEMBL2940750 | 0.77 | HRH3 (0.49) | KDM4EAOC3HRH3HRH4APAF1 | |
| SCHEMBL29684111 | 0.77 | HRH3 (0.49) | KDM4EAOC3HRH3HRH4APAF1 | |
| SCHEMBL38661680 | 0.76 | HRH3 (0.53) | ALDH1A1KDM4EAOC3HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL3714613 | 0.76 | HRH3 (0.47) | KDM4EAOC3HRH3HRH4APAF1 | |
| SCHEMBL92726 | 0.76 | HRH3 (0.53) | ALDH1A1KDM4EAOC3HRH3HRH4 | |
| SCHEMBL7548161 | 0.75 | APAF1 (0.41) | ALDH1A1KDM4EMAPTAOC3HRH3 | |
| SCHEMBL9704853 | 0.75 | APAF1 (0.63) | ALDH1A1KDM4EMAPTAPAF1CDC25B | |
| SCHEMBL21047717 | 0.73 | APAF1 (0.47) | ALDH1A1KDM4EMAPTAOC3HRH3 | |
| SCHEMBL21047573 | 0.71 | APAF1 (0.41) | ALDH1A1KDM4EMAPTAOC3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| EP-1598068-A1 | Antipsychotic heterocycle compounds | Bristol-Myers Squibb Company (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1242072-A4 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6476051-B2 | FOR THERAPY OF PSYCHOSIS, ACUTE MANIA, MILD ANXIETY STATES, OR DEPRESSION IN COMBINATION WITH PSYCHOTIC EPISODES | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| EP-1242072-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1077213-A2 | Inhibition of serotonin reuptake | ELI LILLY AND COMPANY (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6046215-A | A PIPERIDINYLBENZOTHIOPHENES USEFUL FOR TRATING BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-5846982-A | Inhibition of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0812826-A1 | 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072611-A1 | Antipsychotic heterocycle compounds | HTR2C, DRD2, HTR1A | ALDH1A1 1900/4885KDM4E 2070/4885MAPT 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.